Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.84 Insider Own0.40% Shs Outstand230.33M Perf Week-9.43%
Market Cap3.07B Forward P/E- EPS next Y-0.10 Insider Trans-10.97% Shs Float204.86M Perf Month21.58%
Income-189.60M PEG- EPS next Q-0.13 Inst Own83.60% Short Float11.65% Perf Quarter71.15%
Sales71.50M P/S43.01 EPS this Y41.30% Inst Trans6.12% Short Ratio3.81 Perf Half Y233.75%
Book/sh-0.81 P/B- EPS next Y83.90% ROA-45.50% Target Price12.67 Perf Year138.82%
Cash/sh1.42 P/C9.37 EPS next 5Y- ROE145.60% 52W Range3.55 - 15.58 Perf YTD136.70%
Dividend- P/FCF53.02 EPS past 5Y0.90% ROI-43.80% 52W High-21.34% Beta1.90
Dividend %- Quick Ratio1.80 Sales past 5Y-27.50% Gross Margin93.40% 52W Low245.21% ATR0.70
Employees115 Current Ratio1.80 Sales Q/Q353.70% Oper. Margin- RSI (14)45.71 Volatility7.84% 4.75%
OptionableYes Debt/Eq- EPS Q/Q27.00% Profit Margin- Rel Volume2.96 Prev Close13.35
ShortableYes LT Debt/Eq- EarningsNov 02 AMC Payout- Avg Volume6.26M Price12.26
Recom1.60 SMA20-6.91% SMA507.77% SMA20079.95% Volume13,930,632 Change-8.20%
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Nov-24-08Reiterated Lazard Capital Buy $7
Oct-16-08Initiated Merriman Curhan Ford Buy
Sep-28-16 04:48PM  Why Exelixis, Inc. Got Hammered Today at Motley Fool -13.76%
02:21PM  Exelixis (EXEL) Stock Plummets on Cancer Drug Trial Results, Leerink: Selloff Overdone
Sep-26-16 04:36PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
10:15AM  4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate at 24/7 Wall St.
08:33AM  Surging Earnings Estimates Signal Good News for Exelixis (EXEL)
06:02AM  Exelixis Elects Julie Anne Smith to Its Board of Directors Business Wire
06:00AM  Exelixis Announces Collaborator Daiichi Sankyos Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist Business Wire
Sep-22-16 06:50PM  Cramer: I overstayed my welcome on this stock at CNBC
Sep-20-16 04:55PM  Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress Business Wire
11:59AM  2 Bullish Stock Picks and 2 Stocks to Sell Short
08:37AM  3 Reasons Momentum Stock Investors Will Love Exelixis (EXEL)
Sep-17-16 11:13AM  These 3 Stocks Have Doubled Their Investors' Money at Motley Fool
Sep-15-16 11:11AM  Will Exelixis (EXEL) Continue to Surge Higher?
Sep-14-16 07:50PM  Exelixis Wins EU Approval for Cabometyx RCC Treatment (EXEL) at Investopedia +5.69%
04:27PM  Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
02:05PM  Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar
10:03AM  Exelixis (EXEL) Stock Advances, EC Approves Kidney Cancer Drug
09:34AM  4 stocks to watch at MarketWatch
08:20AM  Key FDA Decisions and Trial Results Coming in the Next 2 Months at 24/7 Wall St.
01:00AM  European Commission Approves CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy Business Wire
Sep-13-16 11:25AM  Exelixis Shares Soar on Cancer Therapies (EXEL) at Investopedia
Sep-08-16 08:08AM  The Clear Reason Behind Exelixis, Inc.'s 21% Gain in August at Motley Fool
08:05AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
Sep-07-16 03:44PM  Exelixis Reports Interim Analysis of Liver Cancer Trial Data
12:37PM  4 stocks to watch at MarketWatch
10:40AM  ETFs with exposure to Exelixis, Inc. : September 7, 2016
Sep-06-16 05:08PM  Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma Business Wire
Sep-03-16 02:50PM  3 Biotech Stocks to Buy in September at Motley Fool
Aug-31-16 04:17PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 Business Wire
08:30AM  Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress Business Wire
Aug-26-16 09:00AM  Why Exelixis (EXEL) Could Be Positioned for a Surge
Aug-25-16 09:38AM  4 stocks to watch at MarketWatch
Aug-24-16 12:39PM  Mobileye And Three More Stocks Breaking Out at Forbes -6.37%
08:30AM  Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019 Business Wire
Aug-23-16 12:07PM  4 Biotech Stock Charts You Must See
Aug-22-16 11:25AM  ETFs with exposure to Exelixis, Inc. : August 22, 2016
08:35AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Aug-11-16 01:04PM  EXELIXIS, INC. Financials
12:45PM  ETFs with exposure to Exelixis, Inc. : August 11, 2016
Aug-10-16 11:19AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-09-16 05:26PM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
Aug-04-16 03:52PM  Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues +17.89%
03:46PM  Why Exelixis (EXEL) Stock Is Soaring Today
11:16AM  Correction: Earns-Exelixis story
10:53AM  Don't Roll the Dice on Central Bank News
08:00AM  Earnings Wrap: Transocean (RIG), XPO Logistics (XPO), Exelixis (EXEL), 2 More at Insider Monkey
Aug-03-16 09:10PM  Edited Transcript of EXEL earnings conference call or presentation 3-Aug-16 9:00pm GMT
06:47PM  Exelixis reports 2Q loss
05:00PM  Exelixis Inc Earnings Call scheduled for 5:00 pm ET today
04:13PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:06PM  Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q2 2016 Exelixis Inc Earnings Release - After Market Close
Aug-02-16 10:30AM  Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Aug-01-16 06:38PM  What Awaits Aerie Pharmaceuticals (AERI) in Q2 Earnings?
06:38PM  Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
06:36PM  Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
11:55AM  Exelixis (EXEL) Q2 Earnings Preview: Stock Likely to Gain?
Jul-29-16 03:51PM  Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Jul-23-16 03:23PM  Cancer Stocks: 2 to Buy, 1 to Avoid at Motley Fool
Jul-22-16 10:25AM  Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy Business Wire
Jul-21-16 02:55PM  Exit of Biogen CEO George Scangos could be big for Bay Area biotechs at bizjournals.com
Jul-20-16 08:45AM  5 Stocks to Buy and Hold for the Next Decade at Motley Fool
Jul-12-16 04:19PM  Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016 Business Wire
Jul-11-16 09:23AM  Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Jul-10-16 07:21AM  Here's How Pfizer's Protecting Its Kidney Cancer Drug From New Competitors at Motley Fool
Jul-08-16 09:41AM  The Reason Why Exelixis Skyrocketed 20.5% in June at Motley Fool
06:58AM  Biotech Stock Mailbag: Heron, Exelixis
Jul-01-16 08:23AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase
Jun-30-16 09:09AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase
09:09AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase Company Spotlight
Jun-29-16 09:30AM  Zacks.com featured highlights: Arcos Dorados Holdings, Corcept Therapeutics, Exelixis, Hecla Mining and Lexington Realty Trust
Jun-28-16 03:27PM  Explosive Stocks Under $10
Jun-23-16 11:30AM  Biotech Stock Bounce Picks Up Momentum at Forbes
Jun-15-16 08:03AM  4 Cancer Drug Developers You Need to Have on Your Radar This Year at Motley Fool
06:00AM  'Mad Money' Lightning Round: I'm Sticking With Wells Fargo
Jun-08-16 03:45PM  Exelixis, Inc. Setting New Standard of Care at Motley Fool
09:02AM  Research Coverage Scans Stocks on the Biotechnology Industry for Today
Jun-07-16 03:46PM  Exelixis Up on Positive Kidney Cancer Data on Cabometyx
08:15AM  Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Jun-06-16 05:08PM  Why Transocean, Exelixis, and CF Industries Jumped Today at Motley Fool +11.23%
04:18PM  Exelixis, Inc. Gets Some ASCO Love at Motley Fool
11:21AM  Heres Why These Five Stocks Are Surging Today at Insider Monkey
09:23AM  Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment
07:47AM  Exelixis's stock surges after positive results from trial of kidney cancer treatment at MarketWatch
07:30AM  Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting Business Wire
Jun-05-16 07:30PM  Exelixis Inc Investor/Analyst Briefing to Review Cabozantinib Data at the American Society of Clinical Oncology Annual Meeting scheduled for 7:30 pm ET today
07:35AM  Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Business Wire
07:30AM  Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting Business Wire
Jun-03-16 10:03AM  Exelixis, Inc. Rides Cabometyx's Coattails to Big Gains in May at Motley Fool
May-31-16 03:04PM  These 2 Billionaires Are Dumping Exelixis' Stock. Should You? at Motley Fool
May-27-16 03:31PM  This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales at Motley Fool
May-26-16 04:14PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secu
May-24-16 05:15PM  Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II
May-23-16 09:02AM  Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Business Wire +7.91%
May-16-16 10:26AM  XBI and IHI Rose despite the Biotechnology Sectors Sluggish Week
08:45AM  Exelixis (EXEL) Worth a Look: Stock Up 8.1% in Session
May-12-16 04:50PM  Exelixis, Inc. Prepares for Blastoff at Motley Fool +6.13%
May-11-16 07:40PM  ETFs with exposure to Exelixis, Inc. : May 11, 2016
May-09-16 12:01PM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q1, 2016 By the Numbers
May-05-16 04:05PM  Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10 Business Wire +8.31%
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
WILLSEY LANCEDirectorDec 11Buy4.7850,000239,000494,975Dec 11 07:43 PM
WILLSEY LANCEDirectorDec 10Buy4.9950,000249,550444,975Dec 11 07:43 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Option Exercise5.6351,549290,22188,022Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 16Sale5.8051,549298,98436,473Oct 19 05:08 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Option Exercise5.636003,37837,073Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 13Sale5.806003,48036,473Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Option Exercise5.63300,2761,690,554336,749Oct 14 05:05 PM
Lamb PeterEVP, Discovery Research & CSOOct 12Sale5.84300,2761,753,31236,473Oct 14 05:05 PM